Development of an appropriate simple suspension method for valganciclovir medication.
Gavage tube
HPLC
Simple suspension method
Stability
Valganciclovir
Journal
Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
04
2020
accepted:
12
06
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Valganciclovir (VGC) is essential for preventing cytomegalovirus infections after transplants in adult and pediatric patients. In pediatric patients, VGC tablets have to be pulverized so that they can be delivered via nasogastric tubes. The "simple suspension method" is usually used to suspend tablets in hot water in Japan. However, the optimal suspension conditions and metering methods for preparing VGC suspensions using the simple suspension method are unclear. The purpose of this study was to clarify these issues. VGC tablets were suspended in water (initial water temperature: 25 °C or 55 °C) using the simple suspension method. The residual rate of VGC after it had been suspended in hot water was determined using HPLC. In addition, the suspended solution was passed through 6, 8, and 12 Fr. gavage tubes. The VGC concentrations of suspensions produced using different preparation methods were also determined using HPLC. Cracking the surfaces of VGC tablets and suspending them in water at an initial temperature of 55 °C was effective at dissolving the tablets. The VGC concentration of the suspension remained stable for at least 80 min. Furthermore, the VGC concentration remained stable for 48 h during cold dark storage. Cracking the surfaces of VGC tablets could be a more effective metering method than preparing powder from VGC tablets. In addition, little VGC remained in 6, 8, or 12 Fr. gavage tubes after VGC solution was passed through them. The amount of VGC should be measured carefully when preparing VGC solutions using the simple suspension method.
Sections du résumé
BACKGROUND
BACKGROUND
Valganciclovir (VGC) is essential for preventing cytomegalovirus infections after transplants in adult and pediatric patients. In pediatric patients, VGC tablets have to be pulverized so that they can be delivered via nasogastric tubes. The "simple suspension method" is usually used to suspend tablets in hot water in Japan. However, the optimal suspension conditions and metering methods for preparing VGC suspensions using the simple suspension method are unclear. The purpose of this study was to clarify these issues.
METHODS
METHODS
VGC tablets were suspended in water (initial water temperature: 25 °C or 55 °C) using the simple suspension method. The residual rate of VGC after it had been suspended in hot water was determined using HPLC. In addition, the suspended solution was passed through 6, 8, and 12 Fr. gavage tubes. The VGC concentrations of suspensions produced using different preparation methods were also determined using HPLC.
RESULTS
RESULTS
Cracking the surfaces of VGC tablets and suspending them in water at an initial temperature of 55 °C was effective at dissolving the tablets. The VGC concentration of the suspension remained stable for at least 80 min. Furthermore, the VGC concentration remained stable for 48 h during cold dark storage. Cracking the surfaces of VGC tablets could be a more effective metering method than preparing powder from VGC tablets. In addition, little VGC remained in 6, 8, or 12 Fr. gavage tubes after VGC solution was passed through them.
CONCLUSION
CONCLUSIONS
The amount of VGC should be measured carefully when preparing VGC solutions using the simple suspension method.
Identifiants
pubmed: 32655872
doi: 10.1186/s40780-020-00172-w
pii: 172
pmc: PMC7339454
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Drug Dev Ind Pharm. 2005 Oct;31(9):879-84
pubmed: 16305999
Curr Opin Infect Dis. 2007 Aug;20(4):399-407
pubmed: 17609600
Paediatr Drugs. 2009;11(5):309-21
pubmed: 19725597
Am J Transplant. 2009 Mar;9(3):636-43
pubmed: 19260840
Cancer Chemother Pharmacol. 2012 Aug;70(2):331-8
pubmed: 22526409
Transpl Infect Dis. 2010 Jun;12(3):195-203
pubmed: 20002356
Clin Pharmacokinet. 2005;44(9):969-76
pubmed: 16122283
Am J Health Syst Pharm. 2013 Jul 15;70(14):1230-7
pubmed: 23820460
Cancer Res. 1992 Jul 1;52(13):3577-81
pubmed: 1617627
Contact Dermatitis. 2010 May;62(5):303-8
pubmed: 20536478
Am J Transplant. 2004 Jun;4(6):928-36
pubmed: 15147427
Drugs R D. 2013 Jun;13(2):153-7
pubmed: 23737454
JAMA. 1989 Jun 23-30;261(24):3607-9
pubmed: 2542634